Sugi Predict

Sugi Predict / Compounds / SCHEMBL2492568

SCHEMBL2492568

SCHEMBL2492568

CC(C)NS(=O)(=O)c1ccc(-c2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 4/20 0.68
▸ MMP9 P14780 3/20 0.68
▸ MMP1 P03956 2/20 0.68
▸ MMP13 P45452 2/20 0.68
▸ MMP3 P08254 1/20 0.68
▸ MMP7 P09237 1/20 0.68
▸ CA2 P00918 7/20 0.64
▸ CA12 O43570 6/20 0.64
▸ CA9 Q16790 6/20 0.64
▸ CA14 Q9ULX7 5/20 0.64
▸ CA1 P00915 5/20 0.64
▸ CA3 P07451 1/20 0.59
▸ CA4 P22748 1/20 0.59
▸ CA6 P23280 1/20 0.59
▸ CA5A P35218 1/20 0.59
▸ CA7 P43166 1/20 0.59
▸ CA13 Q8N1Q1 1/20 0.59
▸ CA5B Q9Y2D0 1/20 0.59
▸ MMP8 P22894 1/20 0.54
▸ SLC1A3 P43003 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8575008 0.95 CA2 (0.65) MMP2MMP9MMP1MMP13MMP3
SCHEMBL3599190 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3
SCHEMBL4428929 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3
SCHEMBL4428937 0.81 MMP2 (1.00) MMP2MMP9MMP1MMP13MMP3
SCHEMBL3103313 0.79 MMP2 (0.77) MMP2MMP9MMP1MMP13MMP3
SCHEMBL3617858 0.79 MMP2 (0.77) MMP2MMP9MMP1MMP13MMP3
SCHEMBL6613031 0.79 ADAMTS4 (0.70) MMP2MMP9MMP1MMP13MMP3
SCHEMBL31219603 0.79 MAPT (0.60) MMP2MMP9MMP1MMP13MMP3
SCHEMBL17526270 0.78 CA2 (0.66) MMP2MMP9MMP1MMP13CA2
SCHEMBL23788364 0.78 CA2 (0.57) MMP2MMP9MMP1MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180325878-A1 N-BIARYLAMIDES BAYER IP GMBH (DE) 2018-11-15 — — US disclosed
US-9867812-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2018-01-16 — — US disclosed
US-9867812-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2018-01-16 — — US disclosed
US-9867812-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2018-01-16 — — US disclosed
US-20160310474-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2016-10-27 — — US disclosed
US-20160310474-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2016-10-27 — — US disclosed
US-20160310474-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2016-10-27 — — US disclosed
US-9227964-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 — — US disclosed
US-9227964-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 — — US disclosed
US-9227964-B2 N-biarylamides BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-01-05 — — US disclosed
US-7354930-B2 N-biarylamides BAYER HEALTHCARE AG (DE) 2008-04-08 — — US disclosed
US-7354930-B2 N-biarylamides BAYER HEALTHCARE AG (DE) 2008-04-08 — — US disclosed
US-7354930-B2 N-biarylamides BAYER HEALTHCARE AG (DE) 2008-04-08 — — US disclosed
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2007-05-17 — — US disclosed
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2007-05-17 — — US disclosed
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2007-05-17 — — US disclosed
EP-1651645-B1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2007-02-21 — — EP disclosed
EP-1651645-B1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2007-02-21 — — EP disclosed
EP-1651645-A1 N-BIARYLAMIDES Bayer HealthCare AG (DE) 2006-05-03 — — EP disclosed
WO-2005012299-A1 N-BIARYLAMIDES BAYER HEALTHCARE AG (DE) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180325878-A1 N-BIARYLAMIDES BCHE, BACE2, ACHE MMP2 2108/4885MMP9 2563/4885MMP1 4250/4885
US-20070112023-A1 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement CHRNA7, CHRNA3, CHRNA5 MMP2 3593/4885MMP9 3971/4885MMP1 3584/4885
US-20160310474-A1 N-BIARYLAMIDES BCHE, BACE2, ACHE MMP2 2108/4885MMP9 2563/4885MMP1 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.